Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Jinfang Pharmaceutical-B (02595) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to CICC's research report, Jinfang Pharmaceutical is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - CMB International recently initiated coverage on Jinfang Pharmaceutical, giving it a buy rating with a target price of HKD 51 [1] - Jinfang Pharmaceutical is characterized as an innovative pharmaceutical company rooted in mainland China with a global perspective, supported by a core management team averaging over 20 years of industry experience [1] - The company has established a drug pipeline that includes six clinical-stage candidate drugs [1]
劲方医药-B获纳入恒生综合指数 有望成为港股通标的